Catalent Pharma calls all $350 million 7 7/8% senior notes due 2018

By Marisa Wong

Madison, Wis., July 30 – Catalent Pharma Solutions, Inc. has elected to redeem all of the $350 million principal amount outstanding of its 7 7/8% senior notes due 2018, according to an 8-K filing with the Securities and Exchange Commission.

The notes will be redeemed on Aug. 28 at 101.5% of par plus accrued interest to, but excluding, the redemption date.

The redemption is subject to the completion of an initial public offering by Catalent’s indirect parent, Catalent, Inc., the filing noted.

Catalent is a Somerset, N.J.-based provider of advanced technologies and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer health care companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.